Eloralintide (5mg)
Selective Long-Acting Amylin Receptor Agonist
Eloralintide is listed for amylin-analog research. Catalog vial contents are 5mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Selective amylin receptor agonism
- Sustained-release pharmacokinetics
- Investigational obesity research tool
- Combination-therapy comparator vs cagrilintide
What is Eloralintide?
Eloralintide is a catalog research material in the glp-1 & metabolic category. The listed strengths describe total vial contents for laboratory research.
Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Eloralintide (LY3841136) is a long-acting amylin-receptor agonist developed by Eli Lilly. Like other long-acting amylin analogs it engages the amylin / calcitonin receptor complexes in the hypothalamus and area postrema to drive satiety, gastric-emptying delay, and post-prandial glucagon suppression. Lilly is developing eloralintide both as monotherapy and as a fixed-dose combination with retatrutide-class molecules.
What are the research questions?
- Obesity research: Phase 1 dose-finding reported clinically relevant weight loss across multi-week dosing windows with a favorable tolerability profile.
- Amylin / incretin combination research: Studied as a Lilly-internal pairing partner with GLP-1 / GIP / glucagon triple agonists to test additivity vs incretin monotherapy.
- Selectivity comparator: Used in pharmacology studies comparing selective amylin agonism vs dual amylin / calcitonin agonism on weight, glycemia, and GI signaling.
- Mechanism research: One of only a handful of selective amylin tool molecules available for in-vivo pharmacology research.
What does the published work describe?
Eli Lilly Phase 1 disclosures (2024) established dose-dependent weight loss over 12 weeks in adults with obesity. Phase 2 obesity program initiated 2024; combination Phase 2 with retatrutide-class compounds announced 2025.
What are the limits of this evidence?
The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.
Study references
- Eli Lilly Eloralintide Phase 1 disclosure, 2024
- Eli Lilly Phase 2 obesity & combination announcement, 2025
- Lutz TA. Physiol Behav 2010 — amylin pharmacology
These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Eloralintide handled in the lab?
For Eloralintide, record the product code ELOR-5, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for Eloralintide from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay. For a documented lipid-modified construct, evaluate aggregation and adsorption as well as apparent solubility; check compatibility again after dilution into the final assay buffer.
For Eloralintide, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4300 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Eloralintide form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Eloralintide laboratory protocol should record identity, product code ELOR-5, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Eloralintide
- CAS Number
- 2920514-70-1
- Molecular Weight
- ~4300 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- GLP-1 & Metabolic
- Starting Price
- $179.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Eloralintide has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Eloralintide?
Eloralintide is listed for amylin-analog research. Catalog vial contents are 5mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Eloralintide are available?
The catalog lists 5mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Eloralintide purity results?
Eloralintide has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Eloralintide be handled in the laboratory?
For Eloralintide, record the product code ELOR-5, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Eloralintide?
Choose a solvent for Eloralintide from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay. For a documented lipid-modified construct, evaluate aggregation and adsorption as well as apparent solubility; check compatibility again after dilution into the final assay buffer.
How do I calculate a Eloralintide stock concentration?
For Eloralintide, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4300 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Eloralintide be stored after preparation?
Use the documented storage conditions for the supplied Eloralintide form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Eloralintide lab protocol document?
A Eloralintide laboratory protocol should record identity, product code ELOR-5, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Eloralintide product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this Eloralintide lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is Eloralintide for human use?
No. Eloralintide is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
